Bonadonna G, Santoro A, Viviani S, Lombardi C, Ragni G
Arch Toxicol Suppl. 1984;7:140-5. doi: 10.1007/978-3-642-69132-4_16.
The paper re-emphasizes that intensive prolonged anticancer chemotherapy containing alkylating agents or procarbazine or both produces a high-incidence of gonadal failure, particularly in males. This evidence has been documented mostly in patients with Hodgkin's disease. On the contrary, effective combination regimens, such as ABVD, not including the above mentioned drugs induce a comparatively less and transient germ cell toxicity. In devising chemotherapy for potentially curable neoplastic diseases in young patients efforts should be made to avoid or minimize the potential risk of drug-induced gonadal failure.
该论文再次强调，包含烷化剂或丙卡巴肼或两者的强化延长抗癌化疗会导致性腺功能衰竭的高发生率，尤其是在男性中。这一证据大多记录在霍奇金病患者中。相反，有效的联合方案，如ABVD，不包括上述药物，会引起相对较少且短暂的生殖细胞毒性。在为年轻患者中潜在可治愈的肿瘤疾病设计化疗方案时，应努力避免或最小化药物引起的性腺功能衰竭的潜在风险。
